WO2008115440A1 - Protéines thérapeutiques pharmacodynamiquement améliorées - Google Patents

Protéines thérapeutiques pharmacodynamiquement améliorées Download PDF

Info

Publication number
WO2008115440A1
WO2008115440A1 PCT/US2008/003446 US2008003446W WO2008115440A1 WO 2008115440 A1 WO2008115440 A1 WO 2008115440A1 US 2008003446 W US2008003446 W US 2008003446W WO 2008115440 A1 WO2008115440 A1 WO 2008115440A1
Authority
WO
WIPO (PCT)
Prior art keywords
epo
erythropoietin
peg
protein
composition
Prior art date
Application number
PCT/US2008/003446
Other languages
English (en)
Inventor
Kyle D. Yesland
Markley C. Leavitt
Original Assignee
Synageva Biopharma Corp.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Synageva Biopharma Corp. filed Critical Synageva Biopharma Corp.
Publication of WO2008115440A1 publication Critical patent/WO2008115440A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]

Definitions

  • N-terminally glycosylated therapeutic proteins produced in transgenic avian oviduct tissue i.e., magnum tissue
  • avian oviduct type cells i.e., tubular gland cells
  • EPO Erythropoietin stimulates the proliferation and differentiation of erythroid precursor cells to produce mature erythrocytes, a process known as erythropoiesis. This naturally occurring glycoprotein is produced in the kidney and circulates in the blood to stimulate erythropoiesis in the bone marrow.
  • Human derived EPO is heavily glycosylated with one serine (O)-linked oligosaccharide and three asparagine (N)-linked oligosaccharides.
  • the cDNA for EPO has been cloned and expressed in Chinese hamster ovary (CHO) cells and the resulting carbohydrate composition of the CHO- derived EPO has been extensively characterized.
  • the N-linked oligosaccharides of recombinant EPO produced in CHO cells are mostly tetraantennary complex-type with N-acetyllactosamine repeats, similar to natural human urinary EPO. The same is true for the N-linked oligosaccharides on recombinant human EPO obtained from baby hamster kidney cells.
  • the carbohydrate chains of a glycoprotein may affect its conformation leading to changes in intracellular transport and secretion, solubility and susceptibility to proteases. The carbohydrate chains may also effect in vivo half life by altering routes of clearance and receptor binding properties.
  • EPO glycosylation Studies to examine the role of EPO glycosylation have used EPO treated with glycosidases, EPO synthesized in the presence of inhibitors of carbohydrate addition and/or processing and EPO expressed in cell mutants with a defect in any of the glycosyltransferases.
  • the removal of sialic acid from native and recombinant CHO derived EPO can increase its in vitro biologic activity, possibly by increasing its affinity to receptors on target cells.
  • removal of sialic acid residues destroys the in vivo biologic activity of EPO which correlates with its rapid clearance from the circulation by interaction with hepatic galactosyl receptors.
  • U.S. Patent Application Publication No. 2003/0191291 the disclosure of which is incorporated in its entirety herein by reference, describes proteins having EPO activity that are prepared using non-recombinant technology. The publication further describes such proteins that are polymer-modified in a defined manner.
  • U.S. Patent Application Publication No. 2002/0115833 the disclosure of which is incorporated in its entirety herein by reference, describes an EPO glycoprotein covalently linked to one poly(ethylene glycol) group by way of a specific linkage containing an amide bond with the N-terminal alpha-amino group of the EPO glycoprotein.
  • US Patent Application Publication No. 2006/0182711 the disclosure of which is incorporated in its entirety herein by reference, discloses PEG conjugated to EPO moieties where the EPO moieties have the ability to stimulate red blood cell production.
  • CERA continous erythropoietin receptor activator
  • CERA continous erythropoietin receptor activator
  • Patents that may be related to CERA are US Patent No. 7,128,913, issued October 31, 2006, the disclosure of which is incorporated in its entirety herein by reference and/or U.S. Patent No. 6,340,742, issued January 22,
  • glycolation e.g., PEGylation
  • transgenic avian or poultry derived erythropoietin can produce an erythropoietin product having a high biologic activity and a lengthened biological half life (PK) resulting in a particularly useful EPO.
  • Transgenic avian or transgenic poultry derived erythropoietin as it is natually produced in the oviduct contains little or no sialic acid. This trait has been implicated in the increased biologic activity seen in recombinant EPO produced in the bird oviduct compared to recombinant EPO produced in mammalian cells which is fully sialated.
  • therapeutic proteins in addition to EPO, having an N-linked oligosaccharide produced in the oviduct of an avian, such as chicken or turkey, can be glycolated to yield a therapeutic protein preferable to that of the same pegylated therapeutic produced by pegylating a protein produced using standard cell culture techniques (i.e., mammalian cells in culture).
  • the invention is directed to a therapeutic protein molecule such as an erythropoietin molecule having an N-linked oligosaccharide wherein the N-linked oligosaccharide does not contain a sialic acid, for example, a terminal sialic acid, and the therapeutic protein is chemically bonded to a glycol polymer.
  • a therapeutic protein molecule such as an erythropoietin molecule having an N-linked oligosaccharide wherein the N-linked oligosaccharide does not contain a sialic acid, for example, a terminal sialic acid, and the therapeutic protein is chemically bonded to a glycol polymer.
  • one N-linked oligosaccharide of an asialic therapeutic protein such as EPO does not contain a sialic acid, for example, a terminal sialic acid.
  • two N-linked oligosaccharides of the asialic therapeutic protein such as EPO do not contain a sialic acid, for example
  • three N-linked oligosaccharides of the asialic therapeutic protein such as EPO do not contain a sialic acid, for example, a terminal sialic acid.
  • none of the N-linked oligosaccharides of the asialic therapeutic protein such as EPO contain a sialic acid, for example, a terminal sialic acid.
  • the glycol polymer may be bonded (e.g., covalently bonded) to at least one of an amino group, a hydroxyl group, a sulfhydryl group and a carboxyl group of the therapeutic protein such as EPO. It is contemplated that in addition to covalent bonding the chemical bonding may be ionic bonding, hydrogen bonding and/or Van der Waal's interaction.
  • the invention also includes methods of producing therapeutic protein molecules such as erythropoietin molecules and compositions containing the therapeutic protein molecules of the invention.
  • the invention includes methods of producing therapeutic protein molecules such as erythropoietin molecules which do not contain sialic acid terminally linked to an oligosaccharaide; and covalently bonding a glycol polymer to the therapeutic protein molecule.
  • the invention is directed to producing a composition containing a therapeutic protein such as erythropoietin obtained from a transgenic avian, for example, a transgenic chicken, chemically (e.g., covalently) bonded to a glycol polymer.
  • the therapeutic protein molecules such as erythropoietin molecules of the invention contain an O-linked oligosaccharide. In one embodiment, the therapeutic protein molecules of the invention contain an O-linked oligosaccharide and an N-linked oligosaccharide.
  • the asialic therapeutic protein molecules such as the asialic erythropoietin molecules are exogenous to avians, for example, exogenous to a chicken, turkey or quail.
  • the therapeutic protein molecule are human protein molecules.
  • the therapeutic protein molecule may have the amino acid sequence set forth in Figure 2B.
  • the asialic therapeutic protein such as asialic erythropoietin is produced in an oviduct cell of the transgenic avian, for example, in a tubular gland cell of the avian.
  • the invention also includes pharmaceutical compositions comprising a glycolated asalic therapeutic protein of the invention.
  • the invention is directed to methods of treatment comprising administering to a patient in need thereof glycolated asalic therapeutic protein of the invention such as EPO.
  • the invention is directed to methods of treatment comprising administering to a patient in need thereof a pharmaceutical composition containing a glycolated asalic therapeutic protein of the invention such as EPO.
  • the invention also includes methods of increasing the half-life of an asialic therapeutic protein such as EPO in a patient comprising bonding a glycol polymer to the asialic proetin.
  • the invention is also directed to methods of increasing the red blood cell count in a patient by administering to a patient a glycolated asialic EPO of the invention.
  • the invention contemplates the application of any useful glycol polymer for attachment to a protein, for example, asialic EPO.
  • the glycol polymer may be a polyalkylene glycol such as a polyethylene glycol and a polypropylene glycol.
  • the invention is not limited to glycol polymers of any particular molecular weight.
  • the glycol polymers may have a molecular weight of about 200 to about 400,000, for example, a molecular weight of about 200 to about 20,000.
  • the glycol polymers may have a molecular weight of about 300 to about 200,000, for example, a molecular weight of about 2,000 to about 60,000
  • poultry derived EPO is linked to the PEG molecule shown as Structure I below.
  • X and Y are linking groups selected from NH and O;
  • T is a saccharide or a saccharide derivative
  • F is an activated group, which can react with amino, hydroxyl, carboxyl or thiol groups of the proteins in an aqueous phase without enzymes or other catalysts, as is well know in the art.
  • transgenic poultry derived therapeutic proteins such as EPO are linked to the PEG of Structure VII which is shown below.
  • This PEG is particularly effective when coupled to avian derived EPO.
  • the PEG-EPO yeilds an unexpectedly high PD as can be seen in Figure 6.
  • PEG in Structure VII and VIII represents (CH 2 CH 2 O) n and Protein N in VIII represents the protein such as EPO and an amino group.
  • the invention contemplates the linking of the glycol polymer to the protein by any useful chemical bonding methods known in the art.
  • the glycol polymer is covalently bonded to an amino group of the amino acid sequence.
  • the glycol polymer is covalently bonded to a carboxyl group of the amino acid sequence.
  • the PEG polymer was bound to the poultry derived
  • EPO of the invention as follows. Three parts of 100 mM sodium borate buffer, pH of 9.3, was added to one part of a stock solution of 0.2 to 0.4 mg/ml TPD EPO contained in 10 mM phosphate buffer, pH 6.0. The 35 KDa Glucose PEG (Structure VII) was dissolved in acetonitrile to a concentration of about 20 mg/ml. The PEG solution was slowly added to the EPO solution with stirring until a final EPO:PEG ratio of 10:1 was reached. The reaction mixture was stirred for an additional 60 minutes at room temperature to complete the conjugation reaction.
  • the invention contemplates the employment of any useful purification technique. For example, size exclusion chromatography has can be useful for purification of PEG-EPO produced in accordance with the invention.
  • the therapeutic amino acid sequence obtained from a transgenic avian is a glycoprotein and comprises a glycol polymer covalently bonded to an oligosaccharide of the therapeutic amino acid sequence.
  • the invention contemplates the linking of the glycol polymer to any component of the glycosylation of the therapeutic amino acid sequence.
  • the invention contemplates the linking of the glycol polymer to n-acetyl-galactosamine, n-acetyl- glucosamine, galactose and/or any other carbohydrate structure which may be present in the glycosylation.
  • the invention is drawn to compositions which contain a glycosylated therapeutic amino acid sequence obtained from a transgenic avian, such as a transgenic chicken, wherein the therapeutic amino acid sequence is a glycoprotein associated with a glycol polymer.
  • the glycoprotein may be associated with the glycol polymer by a chemical interaction such as ionic bonding or hydrogen bonding.
  • the glycoprotein is covalently bonded to the glycol polymer.
  • the therapeutic amino acid sequence is an exogenous amino acid sequence.
  • the therapeutic amino acid sequence may be an amino acid sequence endogenous to a human, such as human EPO.
  • N- terminally glycosylated therapeutic proteins in particular, those produced in transgenic avian oviduct tissue such as magnum tissue or avian oviduct type cells in culture such as cell lines derived from tubular gland cells, is enhanced and biological half life decreased, each because there is little or no sialic acid present in the N-linked oligosaccharide structure and as such glycolation (e.g., PEGylation) of such protein can yield a particularly useful therapeutic product.
  • Such therapeutic proteins which can contain an N-linked oligosaccharide include without limitation: Factor VIII, Factor Vila, Factor IX,reteplase tPA, Reteplase tPA (differs from h tPA - 3 of 5 domains deleted), growth hormone (e.g., hGH), thyroid stimulatin hormone (TSH), follicle stimulating hormone (FSH), follitropin-beta, calcitonin, platelet derived growth factor (PDGF), keratinocyte growth factor, insulin-like growth factor- 1 (IGF-I), IGFBP-3, GM-CSF, inteferons such as INF-beta, e.g., INF-betalb and IFN-gamma, e.g., IFN-gamma Ib, interlukins such as IL-3 and IL- 12, TNFR-IgG fragment fusion protein, beta glucocerebrosidase, asparaginase,
  • the invention also includes the PEGylated forms of each of these avian derived proteins, methods of PEGylating each of these avian derived proteins and methods of using each of these PEGylated avian derived proteins, each in accordance with the invention.
  • the asialic glycosyaltion is provided by an oviduct cell of the transgenic avian or an avian oviduct cell in culture or a cell in culture derived at least partially from an avian oviduct cell such as a tubular gland cell.
  • the oviduct cell can be a tubular gland cell. See, for example, US patent application No. 11/454,399, filed June 16, 2006, the disclosure of which is incorporated in its entirety herein by reference.
  • the invention is drawn to oligosaccharide structures being linked to the proteins by linkages provided for in an avian gene expression system.
  • the therapeutic amino acid sequence may be O-glycosylated and/or the therapeutic amino acid sequence may be N-glycosylated.
  • therapeutic proteins produced in accordance with the present invention are soluble in an aqueous phase or are substantially soluble in an aqueous phase.
  • the proteins produced in accordance with the present invention can be nonimmunogenic or have reduce immunogenicity relative to an otherwise identical protein that is not glycolated.
  • Figure IA and IB shows representative deduced N-linked oligosaccharide structures for TPD EPO produced essentially as disclosed in US patent application No. 11/973,853, filed October 11, 2007, the disclosure of which is incorporated in its entirety herein by reference.
  • Figure 2A shows the human EPO nucleotide coding sequence used to produce TPD EPO employed herein.
  • Figure 2B shows the mature EPO amino acid sequence produced from the coding sequence shown in Figure 2A.
  • Figure 3 shows the in vitro activity of poultry derived EPO ( ⁇ ) compared to mammalian cell derived EPO (o).
  • Figure 4 shows the PK measurements for a 5 KDa PEGylated TPD EPO ( ⁇ ) and a 20 KDa PEGylated TPD EPO ( ⁇ ), described in Examples 2 and 3 respectively, compared to non-PEGylated TPD EPO (X) and fully sialated EPO produced in CHO cells (A).
  • the injections were performed subcutaneously which accounts for the initial rise in EPO detected at 4 h.
  • Figure 5 shows the PK measurements for the 40 KDa PEGylated TPD EPO ( ⁇ ) and the 35 KDa PEGylated TPD EPO ( ⁇ ) described in Examples 4 and 5 respectively, compared to non-PEGylated TPD EPO (X) and fully sialated EPO produced in CHO cells (A).
  • the injections were performed subcutaneously which accounts for the initial rise in EPO detected at 4 h.
  • Figure 6 shows the hematocrit measurements for the 35 KDa PEGylated TPD EPO (TPD EPO) (A) and the 40 KDa PEGylated TPD EPO (TPD EPO) ( ⁇ ), as described in Example 6, compared to fully sialated EPO produced in CHO cells (X).
  • avian refers to any species, subspecies or race of organism of the taxonomic class ava, such as, but not limited to, chicken, turkey, duck, goose, quail, pheasants, parrots, finches, hawks, crows and ratites including ostrich, emu and cassowary.
  • the term includes the various known strains of Gallus gallus, or chickens, (for example, White Leghorn, Brown Leghorn, Barred-Rock, Wales, New Hampshire, Rhode Island, Australorp, Minorca, Amrox, California Gray), as well as strains of turkeys, pheasants, quails, duck, ostriches and other poultry commonly bred in commercial quantities. It also includes an individual avian organism in all stages of development, including embryonic and fetal stages.
  • the term “avian” also may denote "pertaining to a bird", such as "an avian (bird) cell.”
  • asialic refers to a therapeutic protein such as erythropoietin that does not contain sufficient sialic acid residues (i.e., N-linked oligosaccharide sialic acid residues) to provide for a therapeutically useful biological half-life of the protein. For example, following administration by injection, more than 95% of 200 IU (16.7 ⁇ g) of asialated EPO will clear from the body of a rat of approximately 250 grams within 4 h or 8 h or 12 h or 24 of injection. Asialaic EPO typically, though not exclusively, contains three N- linked oligosaccharide structures. In one useful embodiment, asialic EPO is produced by heterologous gene expression of an EPO encoding nucleotide sequence in the magnum tissue of a transgenic bird such as a chicken.
  • heterologous refers to a biomolecule such as a nucleic acid or a protein that is not normally found in a particular cell, tissue or other component contained in or produced by an organism.
  • Conjugation buffer is 7.5 mg/ml NaCl, 1.8 mg/ml dibasic sodium phosphate, 1.3 mg/ml monbasic sodium phosphate, 0.1 mg/ml edetate disodium, 0.4 mg/ml Tween 80, pH adjusted to 7.0.
  • cytokine refers to a proteinaceous signalling compound involved in inter-cell communication. Cytokines play a major role in a variety of immunological, inflammatory and infectious diseases. They are also involved in several developmental processes during embryogenesis. Cytokines are produced by a wide variety of cell types, both haemopoietic and non-haemopoietic, and can have effects on nearby cells or cells throughout the organism, sometimes strongly dependent on the presence of other chemicals and cytokines. Cytokines are typically smaller water- soluble proteins, for example, glycoproteins, with a mass of 8-30 kDa.
  • glycolation refers to the addition of a glycol polymer to a molecule such as the addition of a glycol polymer to a protein therapeutic.
  • glycolated refers to a substance, such as a protein therapeutic, to which a glycol polymer has been added.
  • glycol polymer refers to any useful alkene, alkane or alkyne (and combinations thereof) polymer glycol. Examples include, without limitation, polypropylene glycol, polyethylene glycol and polybutylene glycol.
  • PEG polyethylene glycol
  • standard protein therapeutic is a protein therapeutic that does not contain a poultry derived glycosylation pattern and a glycol polymer.
  • a standard protein therapeutic can be a protein therapeutic containing a poultry derived glycosylation pattern or a glycol polymer.
  • substantially means mostly, for example, more than 50%.
  • a protein substantially lacking sialic acid does not have sialic acid attached to at least half of the sites where sialic acid would ordinarily be expected to be attached.
  • an N-linked oligosaccharide substantially excludes or is substantially lacking sialic acid if more than half of the terminal galactose residues on the oligosaccharide do not have an attached sialic acid.
  • Terminal sialic acid and terminal “sialic acid residue” refer to a sialic acid attached to the end of an oligosaccharide chain which is attached to a therapeutic protein. Typically, a terminal sialic acid is attached to a galactose molecule.
  • therapeutic amino acid sequence each refer to an amino acid sequence which in whole or in part makes up a drug.
  • a pharmaceutical composition or therapeutic composition is a liquid formulation that includes one or more protein therapeutics, pharmaceutical proteins, therapeutic amino acid sequences or therapeutic proteins.
  • a "transgenic avian” is any avian, as defined herein, in which one or more of the cells of the avian contain heterologous nucleic acid introduced by manipulation, such as by transgenic techniques.
  • the nucleic acid may be introduced into a cell, directly or indirectly, by introduction into a precursor of the cell by way of deliberate genetic manipulation, for example and without limitation, by microinjection or by infection with a recombinant retrovirus, for example, injection of a recombinant replication deficient retrovirus into the subgerminal cavity of an avian embryo.
  • the heterologous nucleic acid may be an artificial chromosome or may be integrated within a chromosome of the avian, or it may be extrachromosomally replicating DNA.
  • treating or “treating a condition” refers to administering a pharmaceutical composition for preventing disease and/or treating disease.
  • To prevent disease refers to prophylactic treatment of a patient who is not yet ill, but who is susceptible to, or otherwise at risk of, contracting a particular disease.
  • To "treat disease” or “use for therapeutic treatment” refers to administering treatment to a patient already suffering from a disease to ameliorate the disease and improve the patient's well being.
  • “treating” or “treating a condition” is the administration to a subject one or more therapeutic proteins either for therapeutic or prophylactic purposes.
  • Linear in reference to the geometry, architecture or overall structure of a polymer, refers to polymer single monomer derived backbone.
  • Branched in reference to the geometry, architecture or overall structure of a polymer, refers to polymer having 2 or more polymer "arms” extending from a single group, such as an L group that may be derived from an initiator employed in an atom transfer radical polymerization reaction.
  • a branched polymer may possess 2 polymer arms, 3 polymer arms, 4 polymer arms, 5 polymer arms, 6 polymer arms, 8 polymer arms or more.
  • compounds having three or more polymer arms extending from a single linear group are denoted as having a "comb” structure or "comb” architecture.
  • “Pharmaceutically acceptable” composition or “pharmaceutical composition” refers to a composition comprising a compound of the invention and a pharmaceutically acceptable excipient or pharmaceutically acceptable excipients.
  • salt includes, without limitation, acid addition salts including hydrochlorides, hydrobromides, phosphates, sulphates, hydrogen sulphates, alkylsulphonates, arylsulphonates, acetates, benzoates, citrates, maleates, fumarates, succinates, lactates, and tartrates; salts of alkali metal cations such as Na + , K + , Li + (e.g.,
  • NaCl, KCl organic amine salts or alkali earth metal salts such as Mg or Ca salts.
  • “Pharmaceutically acceptable excipient” and “pharmaceutically acceptable carrier” refer to an excipient that can be included in the compositions of the invention and that causes no significant adverse toxicological effect on the patient.
  • pharmaceutically acceptable excipients include water, NaCl, normal saline solutions, lactated Ringer's, normal sucrose, normal glucose and the like.
  • Patient or “subject in need thereof refers to a living organism suffering from or prone to a condition that can be prevented or treated by administering a therapeutic protein of the invention or a pharmaceutical composition containing a therapeutic protein of the invention as provided herein.
  • Non-limiting examples of patients include humans and other mammals and non-mammalian animals.
  • poultry means domesticated birds used for eggs or meat such as chickens and turkeys.
  • “Therapeutically effective amount” refers to an amount of a conjugated biologically active agent or of a pharmaceutical composition useful for treating, ameliorating, or preventing an identified disease or condition, or for exhibiting a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art.
  • the "biological half life” or “biologic half life” of a substance is the pharmacokinetic parameter which specifies the time required for one half of the substance to be removed from an organism following introduction of the substance into the organism.
  • “Reactive group” refers to a functional group that is capable of forming a covalent linkage consisting of one or more bonds to a biologically active agent.
  • the abbreviation “g” means grams.
  • the abbreviation “ml” means milliliters.
  • the abbreviation “mg” means milligrams.
  • the abbreviation “PEG” means polyethylene glycol.
  • the abbreviation “KDa” means kilodalton. " 0 C “ means degrees centigrade.
  • the abbreviation " mM” means millimolar.
  • the abbreviation “ h” means hours.
  • the abbreviation “ mU” means milliunits.
  • the abbreviation “ IU” means international units.
  • the abbreviation “ ⁇ l” means microliters.
  • the abbreviation “ PK” means pharmacokinetics.
  • the abbreviation “ PD” means pharmacodynamics.
  • N-terminally glycosylated therapeutic proteins produced in transgenic avian oviduct tissue (i.e., magnum tissue) or avian oviduct type cells (i.e., tubular gland cells) in culture is enhanced while the pharmacokinetics is decreased since little or no sialic acid is present in the N-linked oligosaccharide structure.
  • Glycolation (e.g., PEGylation) of such protein can yield a particularly useful therapeutic product.
  • a particularly useful aspect of the invention is that glycosylated therapeutic proteins, in particular, human proteins, produced in transgenic avian oviduct tissue (e.g., tubular gland cells) are naturally asialic.
  • the proteins can be easily produced in large quantities in a transgenic avian system.
  • other aspects of the N-linked oligosaccharides of proteins produced in transgenic avians are not shared with oligosaccharides of the same protein produced in mammalian cells. Such differences are readily apparent based upon the knowledge of a practitioner of skill in the art in conjunction with the disclosure of the specification.
  • This invention contemplates the bonding of a water soluble polymer to an asialic therapeutic protein such as EPO.
  • the asialic therapeutic proteins are produced in the oviduct of transgenic birds including transgenic poultry such as transgenic chicken, turkey and quail.
  • the invention specifically contemplates the glycolation, for example, PEGylation, of asialic EPO (e.g., asialic human EPO).
  • Asialic EPO molecules may be produced by avians, including without limitation, chicken, turkey, duck, goose, quail, pheasants, parrots, finches, hawks, crows and ratites including ostrich, emu and cassowary.
  • Figure 1 shows some of the identified N-linked oligosaccharide structures of human EPO (EPO shown in Figure 2B) that were produced in chickens essentially as disclosed in US Patent No. 6,730,822, issued May 4, 2004, the disclosure of which is incorporated in its entirety herein by reference. It can be seen that only one of these structures which has been elucidated may have a single terminal sialic acid residue attached. In one particular embodiment, the invention is drawn to glycolation of this asialic EPO protein produced in chickens.
  • PEG polyethylene glycol
  • PEG is a hydrophilic, biocompatible and nontoxic polymer of general formula H (OCH 2 CH 2 ) nOH, wherein n > 4. Its molecular weight can vary substantially, for example, from 200 to 20,000 Dalton.
  • the invention is not specifically drawn to any particular method of attaching PEG molecules to proteins or any particular molecular weight of PEG employed.
  • glycolating proteins Many useful methods of glycolating proteins are known in the art and the present invention contemplates the employment of each such method.
  • the invention contemplates any useful method of PEGylation to produce therapeutic proteins such as PEGylated asialic EPO as disclosed herein.
  • certain well known methods for PEGylating proteins use compounds such as N-hydroxysuccinimide (NHS)- PEG to attach PEG to free amines, typically at lysine residues or at the N-terminal amino acid.
  • NHS N-hydroxysuccinimide
  • Site specific methods of PEGylation are also included in the present invention.
  • One such method attaches PEG to cysteine residues using cysteine-reactive PEGs.
  • a number of highly specific, cysteine-reactive PEGs with different reactive groups e.g., maleimide, vinylsulfone
  • different size PEGs e.g., 2-40 kDa
  • these PEG reagents selectively attach to "free" cysteine residues, i.e., cysteine residues not involved in disulfide bonds.
  • additional cysteine residues can be introduced at any useful position in the therapeutic protein.
  • the newly added "free" cysteines can serve as sites for the specific attachment of a PEG molecule using cysteine-reactive PEGs.
  • the added cysteine residue can be a substitution for an existing amino acid in a protein, added preceding the amino-terminus of the protein or after the carboxy-terminus of the protein, or inserted between two amino acids in the protein.
  • one of two cysteines involved in a native disulfide bond which may be present in certain therapeutic proteins, may be deleted or substituted with another amino acid, leaving a native cysteine (i.e., the cysteine residue in the protein that normally would form a disulfide bond with the deleted or substituted cysteine residue) free and available for chemical modification.
  • the amino acid substituted for the cysteine would be a neutral amino acid such as serine or alanine.
  • disulfide bonds can be reduced and alkylated with iodoacetimide without impairing biological activity providing targets for deletion or substitution by another amino acid.
  • a cysteine residue is incorporated into the amino acid sequence of a modified TPD EPO protein, employing methods known in the art, for example, recombinant DNA methodologies.
  • methods for preparing a glycolated, for example, PEGylated glycoprotein comprise the steps of (a) reacting the protein with polyethylene glycol, such as a reactive ester or aldehyde derivative of PEG, under conditions whereby the protein becomes attached to one or more PEG groups and (b) obtaining the reaction product(s).
  • polyethylene glycol such as a reactive ester or aldehyde derivative of PEG
  • the optimal reaction conditions for the reactions will be determined case by case based using known parameters for the desired result.
  • glycol polymer molecules such as polyethylene glycol polymer molecules can be "activated" to facilitate coupling of the glycol polymer molecule to the protein in accordance with the invention.
  • Examples of preparation of such activated glycol polymers are provided in the following references which are hereby incorporated by reference: K. Yoshinaga and J. M. Harris, J. Bioact. Comp. Polym., 1, 17-24 (1989); K. Nilsson and K.
  • the invention contemplates the application of any useful glycol polymer to produce glycolated protein therapeutics.
  • the following polymer types are examples of PEG polymers that can be linked to therapeutic proteins disclosed herein such as EPO.
  • X and Y are linking groups selected from NH and O;
  • T is a targeting agent group of a saccharide or its derivatives
  • F is an activated group, which can react with amino, hydroxyl, carboxyl or thiol groups of the proteins in an aqueous phase without enzymes or other catalysts, as is well know in the art. See, for example, Structure VII.
  • a composition of the invention comprisies a erythropoietin molecule comprising an N-linked oligosaccharide wherein the N-linked oligosaccharide substantially excludes sialic acid and the erythropoietin is chemically bonded to a glycol polymer comprising the structure:
  • X is a linking group selected from NH and O;
  • T is a saccharide or a saccharide derivative.
  • P a and P b are selected from the group consisting of polyethylene glycol, polypropylene glycol, which are the same or different;
  • Ri is selected from the group consisting of H, a C M2 substituted or unsubstituted alkyl, a substituted aryl, an aralkyl, and a heteroalkyl;
  • Xi and X 2 independently are linking groups, wherein Xi is (CH 2 ) H , and X 2 is selected from the group consisting of (CH 2 ) n , (CH 2 ) n OCO,
  • F is a functional group capable of reacting with an amino, hydroxyl, carboxyl or thiol groups of the proteins in an aqueous phase without enzymes or other catalysts, as is well know in the art.
  • P 3 and P b are glycols, which are the same or different.
  • P a and P b can be polyethylene glycol; and j are independently an integer from 1 to 12;
  • Ri is selected from the group consisting of H, a Ci -I2 substituted or unsubstituted alkyl, a substituted aryl, an aralkyl, and a heteroalkyl; and
  • F can be a functional group capable of reacting with an amino group, a hydroxyl group or a thiol group of the protein.
  • Example 4 of publication No. 2006/0014666 is a particularly useful PEG molecule in accordance with the invention.
  • the PEG structure shown in Example 4 of publication No. 2006/0014666 is a particularly useful PEG to coupled to poultry derived therapeutic proteins of the invention, including, without limitation, poultry derived therapeutic proteins having an N-linked oligosaccharide.
  • "comb shaped" PEG polymers such as PolyPeg® manufactured by Warwick Effect Polymers, Inc may be used in accordance with the present invention. See, for example, Structure IV below and WO 2004/113394 A2, the disclosure of which is incorporated in its entirety herein by reference.
  • PEG to proteins to provide soluble PEG-protein conjugates.
  • Such methods are contemplated for the attachment of PEG to therapeutic proteins in accordance with the present invention.
  • Glycolation such as PEGylation may be carried out by, for example, an acylation reaction or an alkylation reaction with a reactive or activated polyethylene glycol polymer molecule.
  • protein products produced according to the present invention include PEGylated proteins wherein the PEG group(s) is (are) attached by acyl or alkyl groups.
  • Such products may be mono-PEGylated or poly-PEGylated (e.g., containing 2- 6, and/or 2-5, PEG groups).
  • the PEG groups can be attached to the protein at the alpha or epsilon amino groups of amino acids, but it is also contemplated that the PEG groups could be attached to any group of the protein which is sufficiently reactive to become attached to a PEG group under suitable reaction conditions.
  • Glycolation such as PEGylation by acylation generally can involve reacting an active ester derivative of glycol polymer such as PEG with the protein.
  • the polymer(s) selected can have a single reactive ester group. Any known or subsequently discovered reactive PEG molecule may be used to carry out the PEGylation reaction.
  • a useful activated PEG ester is PEG esterified to N- hydroxysuccinimide (NHS).
  • acylation is contemplated to include, without limitation, the following types of linkages between the protein and a glycol polymer such as PEG: amide, carbamate, urethane, and the like (Chamow (1994), Bioconjugate Chem., 5 (2): 133-140).
  • Reaction conditions may be selected from any of those known in the PEGylation art or those subsequently developed, but should avoid conditions such as temperature, solvent and pH that would inactivate the protein (e.g., asialic EPO) to be modified.
  • Glycolation by acylation can result in a poly-PEGylated protein.
  • the connecting linkage is an amide.
  • the resulting product may be substantially only (e.g., >95%) mono, di- or tri-PEGylated. However, some species with higher degrees of PEGylation may be formed in amounts depending on the specific reaction conditions used. If desired, certain PEGylated species (e.g., mono, di- or tri- PEGylated) may be separated from the mixture by standard purification techniques, including among others, dialysis, salting-out, ultrafiltration, ion-exchange chromatography, gel filtration chromatography and electrophoresis. In one particularly useful embodiment, a substantially pure mono-PEGylated form of the protein is purified in accordance with the invention.
  • Glycolation in accordance with the invention can involve reacting a terminal aldehyde derivative of a glycol polymer such as PEG with the protein in the presence of a reducing agent.
  • the polymer(s) selected can have a single reactive aldehyde group.
  • An exemplary reactive PEG aldehyde is polyethylene glycol propionaldehyde, which is water stable, or mono Cl-ClO alkoxy or aryloxy derivatives thereof. See, for example, US Patent No. 5,252,714, issued October 12, 1993, the disclosure of which is incorporated in its entirety herein by reference. Though glycolation such as PEGylation by alkylation can result in poly-
  • Reductive alkylation to produce a substantially homogeneous population of mono-polymer/protein product can include the steps of:
  • an asialic therapeutic protein such as a glycosyalated, asialic EPO
  • a reactive PEG molecule under reductive alkylation conditions, at a pH suitable to permit selective modification of the alpha amino group at the amino terminus of the protein
  • the reaction can be performed at a pH which allows one to take advantage of the pKa differences between the epsilon amino groups of the lysine residues and that of the alpha amino group of the N-terminal residue of the protein.
  • a pH which allows one to take advantage of the pKa differences between the epsilon amino groups of the lysine residues and that of the alpha amino group of the N-terminal residue of the protein.
  • the pH is lower, a larger excess of polymer to protein will be desired (i.e., the less reactive the N- terminal alpha amino group, the more polymer needed to achieve optimal conditions).
  • the pH is higher, the polymerprotein ratio need not be as large (i.e., more reactive groups are available, so fewer polymer molecules are needed).
  • the pH can fall within the range of 3 to 9, for example, 3 to 6.
  • the reducing agent should be stable in aqueous solution and preferably be able to reduce only the Schiff base formed in the initial process of reductive alkylation.
  • Suitable reducing agents may be selected from sodium borohydride, sodium cyanoborohydride, dimethylamine borane, trimethylamine borane and pyridine borane.
  • a particularly suitable reducing agent is sodium cyanoborohydride.
  • Other reaction parameters such as solvent, reaction times, temperatures and means of purification of products can be determined on a case-by-case basis, based on the published information relating to derivatization of proteins with water soluble polymers.
  • a glycol polymer that contains a reactive group such as an aldehyde can be controlled.
  • the conjugation with the polymer takes place predominantly at the N-terminus of the protein without significant modification of other reactive groups, such as the lysine side chain amino groups, occurs.
  • the preparation can typically be greater than 90% monopolymer/protein conjugate, or greater than 95% monopolymer/protein conjugate, with the remainder of observable molecules being unreacted (i.e., protein lacking the polymer moiety).
  • Glycolation also may be carried out by water soluble polymers having at least one reactive hydroxy group (e.g. polyethylene glycol) that can be reacted with a reagent having a reactive carbonyl, nitrile or sulfone group to convert the hydroxyl group into a reactive Michael acceptor, thereby forming an activated linker useful in modifying various proteins to provide improved biologically-active conjugates.
  • Reactive carbonyl, nitrile or sulfone means a carbonyl, nitrile or sulfone group to which a two carbon group is bonded having a reactive site for thiol-specific coupling on the second carbon from the carbonyl, nitrile or sulfone group. See, for example, WO 92/16221, the disclosure of which is incorporated in its entirety herein by reference).
  • the activated linkers for attachment of glycol polymers (e.g., PEG polymers) to the protein can be mono functional, bifunctional, or multifunctional.
  • Useful reagents having a reactive sulfone group that can be used in the methods include, without limitation, chlorosulfone, vinylsulfone and di vinyl sulfone.
  • the glycol polymer is activated with a Michael acceptor.
  • WO 95/13312 the disclosure of which is incorporated in its entirety herein by reference, describes, among other things, water soluble sulfone-activated PEGs which are highly selective for coupling with thiol moieties instead of amino moieties on molecules and on surfaces. These PEG derivatives are stable against hydrolysis for extended periods in aqueous environments at pHs of about 11 or less, and can form linkages with molecules to form conjugates which are also hydrolytically stable.
  • the linkage by which the PEGs and the biologically active molecule are coupled includes a sulfone moiety coupled to a thiol moiety and has the structure PEG-SO 2 -CH 2 --CH 2 ⁇ S--W, where W represents the biologically active molecule, and wherein the sulfone moiety can be vinyl sulfone or an active ethyl sulfone.
  • Two useful homobifunctional derivatives are PEG-bis-chlorosulfone and PEG-bis-vinylsulfone.
  • the protein is glycolated (e.g., PEGylated) by the coupling of a glycol polymer to the protein through glycosylations present on the protein (e.g., through an oligosaccharide structure of glycosylated asialic therapeutic protein i.e., having an N-linked oligosaccharide and produced in avian oviduct tissue such as chicken magnum tissue). Therefore, the invention includes proteins having glycol polymers such as polyethylene glycol coupled to a glycosylation structure of the glycosylated therapeutic protein and methods of making such glycosylated-glycolated protein.
  • the invention is drawn to a process for the glycolation of a glycosylated protein, comprising activating a polyalkylene glycol, reacting the activated polyalkylene glycol with a diamino compound, whereby the activated polyalkylene glycol is coupled to the diamino compound through one of its amino groups, oxidizing a therapeutic protein to activate at least one glycosyl group therein, and reacting the polyalkylene glycol coupled to the diamino compound with the oxidized glycosyl group in the protein.
  • the invention can include a process for the PEGylation of a glycosylated protein comprising:
  • the invention can further be used to produce a wide range of desired glycolated and poultry derived therapeutic proteins (e.g., avian derived glycosylated therapeutic proteins) such as fusion proteins, growth hormones, cytokines, structural proteins and enzymes including human growth hormone, interferon, lysozyme, and ⁇ -casein.
  • desired glycolated and poultry derived therapeutic proteins e.g., avian derived glycosylated therapeutic proteins
  • desired glycolated and poultry derived therapeutic proteins e.g., avian derived glycosylated therapeutic proteins
  • desired glycolated and poultry derived therapeutic proteins e.g., avian derived glycosylated therapeutic proteins
  • desired glycolated and poultry derived therapeutic proteins e.g., avian derived glycosylated therapeutic proteins
  • fusion proteins e.g., growth hormones, cytokines, structural proteins and enzymes including human growth hormone, interferon, lysozyme, and ⁇ -casein.
  • proteins contemplated for modification as disclosed herein include, but are not limited to, albumin, ⁇ -1 antitrypsin, antithrombin III, collagen, factors VIII, IX, X (and the like), fibrinogen, hyaluronic acid, insulin, lactoferrin, protein C, erythropoietin (EPO), granulocyte colony- stimulating factor (G-CSF), granulocyte macrophage colony- stimulating factor (GM-CSF), tissue-type plasminogen activator (tPA), somatotropin, and chymotrypsin.
  • Modified immunoglobulins and antibodies including immunotoxins which bind to surface antigens on human tumor cells and destroy them, can also be produced as disclosed herein.
  • proteins which can be produced by transgenic avians and are contemplated for glycolation as disclosed herein include, without limitation, factor VIII, b-domain deleted factor VIII, factor Vila, factor IX, anticoagulants; hirudin, alteplase, tpa, reteplase, tpa, tpa - 3 of 5 domains deleted, insulin, insulin lispro, insulin aspart, insulin glargine, long-acting insulin analogs, hgh, glucagons, tsh, follitropin-beta, fsh, gm-csf, pdgh, ifn alpha2, ifn alpha2a, ifn alpha2b, inf-aphal, ifn-beta, inf-beta Ib, ifn- beta Ia, ifn-gamma (e.g., 1 and 2), il-2, ⁇ l- 11, hbsag, ospa,
  • the invention contemplates the modification of poultry derived immunoglobulins and other multimeric proteins in accordance with the invention.
  • therapeutic antibodies that may be modified in methods of the invention include but are not limited to HERCEPTINTM (Trastuzumab) (Genentech, CA) which is a humanized anti-HER2 monoclonal antibody for the treatment of patients with metastatic breast cancer; REOPROTM (abciximab) (Centocor) which is an anti- glycoprotein Ilb/IIIa receptor on the platelets for the prevention of clot formation; ZENAPAXTM (daclizumab) (Roche Pharmaceuticals, Switzerland) which is an immunosuppressive, humanized anti-CD25 monoclonal antibody for the prevention of acute renal allograft rejection; PANOREXTM which is a murine anti-17-IA cell surface antigen IgG2a antibody (Glaxo Wellcome/Centocor); BEC2 which is a murine antiidiotype (GD3 epitope) IgG antibody
  • a poultry derived protein contemplated for modification as disclosed herein is an antibody capable of selectively binding to an antigen which may be generated by combining at least one immunoglobulin heavy chain variable region and at least one immunoglobulin light chain variable region, for example, cross-linked by at least one disulfide bridge.
  • the combination of the two variable regions generates a binding site that binds an antigen using methods for antibody reconstitution that are well known in the art.
  • therapeutic proteins disclosed herein that do not normally or naturally contain an N-linked oligosaccharide can be produced recombinantly in the avian oviduct with an altered amino acid sequence such that the protein includes a site for an N-linked oligosaccharide, as is understood in the art.
  • the proteins disclosed herein can be produced recombinantly in the avian oviduct such that additional sites for N-linked oligosaccharides are present on the protein, as is understood in the art.
  • the EPO e.g., human EPO
  • the EPO not having the oligosaccahride structures required for useful biological activity is produced by heterologous gene expression in yeast (e.g., Pichia pastoris, Saccharomyces cerevisiae) for use in accordance with the invention.
  • yeast e.g., Pichia pastoris, Saccharomyces cerevisiae
  • human EPO can be produced in bacteria and chemically glycosylated (e.g., E. coli, Bacillus sp.) for use in accordance with the present invention.
  • proteins of the invention may be administered in raw form, it can be useful to administer the protein as part of a pharmaceutical composition or pharmaceutical formulation.
  • compositions comprising a glycolated protein of the invention or a pharmaceutically acceptable derivative thereof together with one or more pharmaceutically acceptable carriers thereof and, optionally, other therapeutic and/or prophylactic ingredients.
  • the carrier(s) must be "acceptable” in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • compositions include those suitable for oral, rectal, nasal, topical (including buccal and sub-lingual), vaginal or parenteral (including intramuscular, subcutaneous and intravenous) administration or in a form suitable for administration by inhalation or insufflation.
  • the formulations may, where appropriate, be conveniently presented in discrete dosage units and may be prepared by any of the methods well known in the art of pharmacy and medicine. All methods include the step of bringing into association the active compound with liquid carriers or finely divided solid carriers or both and then, if necessary, shaping the product into the desired formulation.
  • compositions suitable for oral administration may conveniently be presented as discrete units such as capsules, cachets or tablets each containing a predetermined amount of the active ingredient; as a powder or granules; as a solution; as a suspension; or as an emulsion.
  • the active ingredient may also be presented as a bolus, electuary or paste.
  • Tablets and capsules for oral administration may contain conventional excipients such as binding agents, fillers, lubricants, disintegrants, or wetting agents.
  • the tablets may be coated according to methods well known in the art.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for constitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, nonaqueous vehicles (which may include edible oils) or preservatives.
  • the compounds according to the invention may also be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-f ⁇ lled syringes, small volume infusion or in multi-dose containers with an added preservative.
  • compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilization from solution, for constitution with a suitable vehicle, e.g., sterile, pyrogen-free water, before use.
  • the compounds according to the invention may be formulated as ointments, creams or lotions, or as a transdermal patch.
  • Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will in general also contain one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents or coloring agents.
  • Formulations suitable for topical administration in the mouth include lozenges comprising active ingredient in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.
  • compositions suitable for rectal administration wherein the carrier is a solid are most preferably represented as unit dose suppositories.
  • Suitable carriers include cocoa butter and other materials commonly .used in the art, and the suppositories may be conveniently formed by a mixture of the active compound with the softened or melted carrier(s) followed by chilling and shaping in molds.
  • Formulations suitable for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient, such carriers as are known in the art to be appropriate.
  • the compounds of the invention may be used as a liquid spray or dispersible powder or in the form of drops.
  • Drops may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing agents, solubilizing agents or suspending agents. Liquid sprays are conveniently delivered from pressurized packs.
  • the compounds according to the invention are conveniently delivered from an insufflator, nebulizer or a pressurized pack or other convenient means of delivering an aerosol spray.
  • Pressurized packs may comprise a suitable propellant such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • the compounds according to the invention may take the form of a dry powder composition, for example a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the powder composition may be presented in unit dosage form in, for example, capsules or cartridges or, e.g., gelatin or blister packs from which the powder may be administered with the aid of an inhalator or insufflator.
  • the above described formulations adapted to give sustained release of the active ingredient may be employed.
  • compositions according to the invention may also contain other active ingredients such as antimicrobial agents, or preservatives.
  • the compounds of the invention may be used in combination with other therapeutic agents.
  • poultry derive glycosylated- glycolated human interferon alpha e.g., interferon alpha 2b
  • ribavirin and/or virimidine to treat viral infections such as hepatitis C.
  • Compositions or compounds of the invention can be used to treat a variety of conditions.
  • treatment therapies are known to practitioners of skill in the art in which protein therapeutics such as erythropoietin are employed.
  • the present invention contemplates that the protein therapeutics produced in accordance with the invention can be employed to treat such conditions. That is, the invention contemplates the treatment of a condition known to be treatable by a protein therapeutic such as EPO by administering a protein therapeutic produced in accordance with the invention, such as glycolated asialic EPO.
  • the dosage administered will vary depending upon known factors such as age, health and weight of the recipient, type of concurrent treatment, frequency of treatment, and the like. Usually, a dosage of active ingredient can be between about 0.0001 and about 10 milligrams per kilogram of body weight. Precise dosage, frequency of administration and time span of treatment can be determined by a physician skilled in the art of therapeutic protein administration. The following examples are methods useful for the production of therapeutics in accordance with the present invention; however, it is understood that the invention is not limited to any particular method of making therapeutics of the invention and the invention encompasses all such useful methods known in the art and those yet to be devised.
  • the biological activity of poultry derived EPO was assessed by an in vitro cell proliferation assay that quantifies the effect of EPO on Human Erythroleukemia (TF-I) cells.
  • TF-I Human Erythroleukemia
  • a comparison of the activity for transgenic poultry derived human EPO (TPD EPO) and human EPO obtained from recombinant CHO cells (CHO EPO) was determined and is shown in Figure 3.
  • the cells were grown in RPMI- 1640 medium with 2mM L-glutamine, ImM sodium pyruvate, 5OmM 2-mercaptoethanol, 2ng/ml rhGM-CSF and 10% fetal bovine serum. For 24 - 48 hr preceding the assay the cells were cultured in 5ng/ml GM-CSF. The cells were then washed 3 times with cold RPMI and re-suspended in cell culture medium (without GM-CSF). The cell density of the suspension was adjusted to IxIO 5 cells/ml and lOOul of the cell suspension was added to each well in a 96-well assay plate.
  • TPD EPO 160ng/ml
  • the assay plate was incubated at 37 0 C in 5% CO 2 for 5 days at which time an MTT-assay was performed which is based on the principle that metabolically active cells are able to reduce 3-(4,5-dimethylthiazol-2,5-diphenyl) tetrazolium bromide (MTT) to a colored product, which can be quantified spectrophotometrically.
  • MTT 3-(4,5-dimethylthiazol-2,5-diphenyl) tetrazolium bromide
  • the same assay was performed using CHO EPO.
  • the optical density (OD) was determined for each EPO concentration for both the TPD EPO plate and CHO EPO plate.
  • the assays were performed in triplicate for each EPO and the ED 50 was determined as shown in Figure 3.
  • the ED 50 of TPD EPO was shown to be approximately 7 times that of CHO EPO.
  • the conjugation reaction was initiated by mixing 5 ml of the TPD EPO stock with 2.4 ml of conjugation buffer followed by the addition of 400 ⁇ l of the MPEG-SC-20KDa stock solution resulting in a PEG: EPO molar ratio of about 85:1.
  • the reaction was allowed to proceed overnight at room temperature.
  • glycine was added to the reaction mix to a concentration of 20 mM, and the mix was allowed to stand for 20 minutes at room temperature.
  • the final volume of the PEG-EPO conjugation mix was about 7.8 ml, containing about 96 ⁇ g/ml EPO.
  • EPO EPO
  • serum samples were taken from the rat using standard methodologies at 4 h, 24 h, 48 h and 72 h time points. Serum was harvested from the blood samples, diluted 1 :10 and EPO was quantified in pg/ml by ELISA using a human erythropoietin immunoassay kit (StemCell Technologies, Inc).
  • EPO type the assays were performed in 3 rats (assays were performed in duplicate at each time point for each rat and averaged) and averages for the three rats are shown graphed.
  • the PK measurement for PEG conjugated TPD EPO is shown as line “ 2 " in Figure 4 (20 KDa PEG).
  • Line “ 4 " in Figure 4 shows the measured PK for non-PEGylated TPD EPO and
  • line “ 3 " shows the measured PK for EPO produced in CHO cells.
  • MPEG-SC-20KDa average molecular weight of 20 KDa
  • This PEG structure also represents the activated PEG molecule employed in Example 3, having an average molecular weight of 5 KDa.
  • the PEG molecule is disclosed in one or more of US Patent No. 5,122,614, issued June 16, 1992; US Patent No. 5,612,460, issued March 18, 1997; US Patent No. 6,602,498, issued August 5, 2003; US Patent No. 6774,180, issued August 10, 2004; and US patent publication No. 2006/0286657, published December 21, 2006. The disclosures of each of these four issued patents and one published patent application are incorporated in their entirety herein by reference.
  • the reaction was initiated by mixing 5 ml of EPO stock with 588 ⁇ l of conjugation buffer and then adding 294 ⁇ l of the PEG stock solution resulting in PEG:EPO molar ratio of about 25:1.
  • the reaction was allowed to proceed over night at room temperature.
  • glycine was added to the reaction mix to a concentration of 20 mM, and the mix was allowed to stand for 20 minutes at room temperature.
  • the final volume of the PEG-EPO conjugation mix was about 5.88 ml, containing about 129 ⁇ g/ml EPO.
  • PK measurements approximately 200 IU of each EPO (16.7 ⁇ g of EPO) was injected into a rat. Blood samples were taken from the rat using standard methodologies at 4 h, 24 h, 48 h and 72 h time points. Serum was harvested from the blood samples, diluted 1:10 and EPO was quantified in pg/ml by ELISA using a human erythropoietin immunoassay kit (StemCell Technologies, Inc). For each EPO type injected, the assays were performed in 3 rats (assays were performed in duplicate at each time point for each rat and averaged) and averages for the three rats are shown graphed. The PK measurement for PEG conjugated TPD EPO is shown as line " 1 " in Figure 4 (5 KDa
  • Line “ 4 " in Figure 4 shows the measured PK for non-PEGylated TPD EPO and line “ 3 " shows the measured PK for EPO produced in CHO cells.
  • the reaction was allowed to proceed 2 to 4 h at room temperature.
  • glycine was added to the reaction mix to a concentration of 20 mM, and the mix was allowed to stand for 20 minutes at room temperature.
  • the final reaction volume was 8.5 ml.
  • the PK measurement for PEG conjugated TPD EPO is shown as line “ 2 " in Figure 5 (40 KDa PEG).
  • Line “ 3 " in Figure 5 shows the measured PK for non-PEGylated TPD EPO and
  • line “ 4 " shows the measured PK for EPO produced in CHO cells.
  • EPO EPO
  • serum samples were taken from the rat using standard methodologies at 4 h, 24 h, 48 h and 72 h time points. Serum was harvested from the blood samples, diluted 1 :10 and EPO was quantified in pg/ml by ELISA using a human erythropoietin immunoassay kit (StemCell Technologies, Inc). The assays for each EPO type were performed in 3 rats (assays were performed in duplicated at each time point for each rat and averaged) and averages for the three rats are shown graphed.
  • the PK measurement for conjugated TPD EPO is shown as line “ 1 " in Figure 5 (GLUC-NHS-35KDa PEG).
  • Line “ 3 " in Figure 5 shows the measured PK for non-PEGylated TPD EPO and
  • line “ 4 " shows the measured PK for fully sialated EPO produced in CHO cells.
  • GLUC-NHS-35KDa PEG average molecular weight of 35 KDa.
  • This PEG molecule is disclosed in US patent publication No. 2006/0014666, published January 19, 2006, the disclosure of which is incorporated in its entirety herein by reference.
  • This PEG is particularly useful in accordance with the invention and is specifically contemplated for use with each transgenic avian (e.g., poultry such as chicken) derived therapeutic protein disclosed herein.
  • EPO conjugated with 40 KDa NHS Y-PEG of Example 4 and the EPO conjugated with the linear GLUC-NHS-35KDa PEG of Example 5 were each separated from non-pegylated EPO (to greater than 90% purity) by chromatography using a 5 ml HiTrap® SPFF column (GE Life Sciences). Briefly, an elution gradient was run in 50 mM NaOAc (pH 4.0) with a starting NaCl concentration of 0 M run to a final concentration of 0.5 M. The PEGylated EPO eluted at about 0.35 M NaCl and the non- PEGylated at about 0.5 M.
  • PD hematocrit
  • the graphed data in Figure 6 shows the increase in hematocrit for TPD EPO conjugated to linear GLUC-NHS-35KDa PEG and for TPD EPO conjugated to 40 KDa
  • O-PEG-p-amino benzyl ether is diazotized in aqueous solution at 0 0 C with nitrous acid.
  • aqueous solution of 0.25% glycosylated Factor VIII produced as disclosed in US Patent No. 6,730,822, issued May 4, 2004, is added and the mixture is kept at 0 0 C for 2 hours.
  • the solution is dialysed at 5 0 C to 10 0 C to yield glycosylated-PEGylated Factor VIII.
  • PEG 750 2.0 g is dissolved in 30 ml of liquid ammonia and the solution is treated with sodium until a blue color persists for 5 minutes. The ammonia is allowed to evaporate on a stream of dry nitrogen. The residue is treated with 5 ml of methyl chloroacetate and the mixture is allowed to stand overnight at room temperature followed by heating to 100 0 C for 1 hour. The excess reagent is removed under reduced pressure to provide PEG-methyl carbomethoxy ester. Activation of PEG
  • Interferon betalb 1.0 g of oxirane-PEG and 50 mg of human interferon betalb produced as disclosed in US Patent No. 6,730,822, issued May 4, 2004, in buffer solution (pH 8.5) are allowed to react at room temperature for 48 hours. The solution is dialyzed to yield poultry derived N-glycosylated-PEGylated interferon betalb.
  • the triethylammonium chloride is then filtered off using a sintered glass funnel.
  • the product is filtered, washed with ether to remove all of the yellow color, and recrystallized from acetonitrile-ether.
  • the product is then assayed spectrophotometrically by the release of p-nitrophenol by e-amino-n-caproic acid
  • Coupling Buffer 0.05 M sodium acetate
  • 0.5 mg of poultry derived human FSH is buffer exchanged into the coupling buffer using an NAP-10 (Pharmacia) desalting column.
  • NAP-10 Pulsacia
  • To the poultry derived protein solution is added 0.1 ml of freshly prepared 100 mM sodium m-periodate (NaIO 4 ). The solution is mixed gently, and the sealed reaction vessel is shielded from light and incubated at room temperature for 30 minutes.
  • To stop the reaction the sample is passed through a NAP-10 desalting column and is equilibrated with wash buffer. The column is eluted with the conjugation buffer.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des compositions contenant un oligosaccharide lié à N présentant peu ou pas de résidus d'acide sialique terminal qui est lié à une protéine thérapeutique reliée à un polymère de glycol.
PCT/US2008/003446 2007-03-15 2008-03-14 Protéines thérapeutiques pharmacodynamiquement améliorées WO2008115440A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91819807P 2007-03-15 2007-03-15
US60/918,198 2007-03-15

Publications (1)

Publication Number Publication Date
WO2008115440A1 true WO2008115440A1 (fr) 2008-09-25

Family

ID=39766241

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/003446 WO2008115440A1 (fr) 2007-03-15 2008-03-14 Protéines thérapeutiques pharmacodynamiquement améliorées

Country Status (1)

Country Link
WO (1) WO2008115440A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030088375A (ko) * 2002-05-13 2003-11-19 주식회사 바이오폴리메드 약물의 간세포 표적화를 위한 생물학적 활성 고분자 결합체
KR20060120141A (ko) * 2003-11-24 2006-11-24 네오스 테크놀로지스, 인크. 글리코페질화 에리트로포이에틴
US20060287224A1 (en) * 2003-11-24 2006-12-21 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20070087961A1 (en) * 2004-03-11 2007-04-19 Wolfram Eichner Conjugates of hydroxyalkyl starch and erythropoietin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20030088375A (ko) * 2002-05-13 2003-11-19 주식회사 바이오폴리메드 약물의 간세포 표적화를 위한 생물학적 활성 고분자 결합체
KR20060120141A (ko) * 2003-11-24 2006-11-24 네오스 테크놀로지스, 인크. 글리코페질화 에리트로포이에틴
US20060287224A1 (en) * 2003-11-24 2006-12-21 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
US20070087961A1 (en) * 2004-03-11 2007-04-19 Wolfram Eichner Conjugates of hydroxyalkyl starch and erythropoietin

Similar Documents

Publication Publication Date Title
Sinclair et al. Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins
EP1432802B1 (fr) Erythropoietine pegylee et diglycosylee
US7867481B2 (en) Method of treating anemia by administering IL-1ra
CN101600448B (zh) 甘油连接的peg化的糖和糖肽
FI108140B (fi) Menetelmä ja välineitä kantasolutekijän valmistamiseksi, valmistetun tuotteen käyttö, sitä sisältävä tarvikepakkaus sekä menetelmä kantasolutekijän vasta-aineen valmistamiseksi
CZ20002386A3 (cs) Erythropoetinový konjugát
CA2607844C (fr) Polypeptides g-csf pegyles et procedes de production correspondants
US20070092486A1 (en) Glycolated and glycosylated poultry derived therapeutic proteins
CN101703760A (zh) 用于预防和治疗贫血的方法以及组合物
CZ301833B6 (cs) Konjugát erytropoetinu s polyethylenglykolem, zpusob jeho prípravy a lécivo pro lécení anemie s jeho obsahem
CN102153643B (zh) 粒细胞集落形成刺激因子(g-csf)的突变体及其化学缀合多肽
US8389695B2 (en) Selenium containing modifying agents and conjugates
US8124732B2 (en) Composition comprising isolated human CTLA4-Fc fusion protein produced in a transgenic chicken
RU2665802C2 (ru) Слитый белок на основе рекомбинантного иммунорегуляторного белка ганодермы и сывороточного альбумина человека, способ его получения, а также его применение
JP2006521372A (ja) 生物学的活性物質と生体適合性高分子の１：１接合体、この製造方法とこれを含む薬学組成物
KR100521309B1 (ko) 당쇄화된 인간 과립구 형성인자
CN103619358B (zh) 药物制剂
US20080171696A1 (en) Pharmacodynamically enhanced therapeutic proteins
CA2092542A1 (fr) Multiplicateur d'une cellule souche hematopoietique
WO2008115440A1 (fr) Protéines thérapeutiques pharmacodynamiquement améliorées
CN106029105A (zh) 一种制备聚乙二醇化蛋白的组合物的方法
KR20130137966A (ko) 생체적합성 고분자가 접합된 단백질 및 이의 제조방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08742102

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08742102

Country of ref document: EP

Kind code of ref document: A1